Recce Pharmaceuticals Ltd added to WHOs list

Recce Pharmaceuticals Ltd (ASX: RCE) has announced that its primary candidate, RECCE 327 (R327), has been added to the World Health Organization’s (WHO) report of antibacterial agents in clinical and preclinical development. This recognition highlights the significance of R327 in combating antimicrobial resistance and its unique mechanism of action as an adenosine triphosphate (ATP) production disruptor. The WHO report covers antibacterial agents worldwide, evaluating their potential to address infections caused by priority pathogens.

R327 is an ATP production disruptor, the only compound in this category. By targeting the disruption of ATP production in bacterial cells, R327 has the potential to be effective against both Gram-positive and Gram-negative pathogens, making it a promising antimicrobial agent.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com